Tyra Biosciences, Inc. TYRA
We are a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology.
Our in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help us design and predict which product candidates may demonstrate the highest potency, selectivity and tolerability in the clinic. Through this approach, we have built a wholly-owned pipeline of oral small molecule product candidates focused on targets that have previously been considered difficult-to-drug.
Our FGFR3 Programs—oral dabogratinib (formerly TYRA-300) for Urothelial Cancers and Skeletal Dysplasia
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D | $102.9M | $80.1M | $62.5M | $43.0M | $20.6M | $7.2M | — |
| SG&A | $29.8M | $24.1M | $17.4M | $15.9M | $5.7M | $2.1M | — |
| Total operating expenses | $132.8M | $104.2M | $79.9M | $58.9M | $26.3M | $9.3M | — |
| Operating income | -$132.8M | -$104.2M | -$79.9M | -$58.9M | -$26.3M | -$9.3M | — |
| Pre-tax income | -$119.9M | -$86.5M | -$69.1M | -$55.3M | -$26.3M | -$9.3M | — |
| Income tax | $0 | $0 | $0 | $2.0K | $1.0K | $1.0K | — |
| Net income | -$119.9M | -$86.5M | -$69.1M | -$55.3M | -$26.3M | -$9.3M | — |
| EPS, basic | -2.01 | -1.51 | -1.62 | -1.32 | -1.91 | — | — |
| EPS, diluted | -2.01 | -1.51 | -1.62 | -1.32 | -1.91 | -6.05 | — |
| Shares, diluted (wtd. avg.) | 59.6M | 57.2M | 42.7M | 41.9M | 13.8M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $77.4M | $92.0M | $59.0M | $252.2M | $302.4M | $15.5M | $108.0K |
| Total current assets | $265.4M | $347.5M | $211.7M | $257.3M | $304.1M | $15.3M | — |
| Property, plant and equipment | $1.3M | $1.7M | $1.6M | $1.1M | $1.0M | $297.0K | — |
| Total assets | $282.6M | $363.6M | $225.9M | $266.2M | $306.7M | $16.0M | — |
| Accounts payable | $1.2M | $590.0K | $4.7M | $1.1M | $599.0K | $664.0K | — |
| Total current liabilities | $18.1M | $14.6M | $15.3M | $5.7M | $3.6M | $1.9M | — |
| Total liabilities | $23.4M | $20.4M | $21.6M | $8.4M | $5.0M | $2.0M | — |
| Retained earnings | -$371.3M | -$251.3M | -$164.8M | -$95.7M | -$40.4M | -$14.1M | — |
| Total equity | $259.2M | $343.2M | $204.3M | $257.8M | $301.7M | -$13.6M | -$4.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$95.1M | -$69.8M | -$50.1M | -$50.3M | -$23.7M | -$7.8M | — |
| Depreciation and amortisation | $546.0K | $519.0K | $357.0K | $296.0K | $140.0K | $47.0K | — |
| Stock-based compensation | $28.0M | $22.8M | $13.5M | $10.6M | $2.9M | $439.0K | — |
| Capital expenditure | $141.0K | $664.0K | $770.0K | $559.0K | $661.0K | $312.0K | — |
| Investing cash flow | $72.5M | -$98.4M | -$144.6M | -$559.0K | -$645.0K | -$312.0K | — |
| Financing cash flow | $8.1M | $202.1M | $1.5M | $632.0K | $311.3M | $23.4M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-085490.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$9.3M | -$26.3M | -$55.3M | -$69.1M | -$86.5M | -$119.9M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Item 5.02
- Results announced Item 2.02
- Other event Item 8.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |